Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting

Fig. 1

miR-182 promoter methylation frequency is higher in elderly or unfit AML patients than in NC samples. A MethylTarget™ assay was performed to analyze DNA methylation percentage of CpG islands 3 in 94 elderly or unfit AML patients and 20 NC samples. B The methylation frequency of individual CpG sites by MethylTarget™ assay was analyzed in 94 elderly or unfit AML patients and 20 NC samples. C and D Bisulfite-genomic sequencing was used to assess the methylation frequency in two AML patients with miR-182 promoter hypermethylation and two AML patients with miR-182 promoter hypomethylation. Four colonies were shown for each AML sample. Each row of the circle represents an individual clone. Empty and black circles represent unmethylated and methylated CpG dinucleotides, respectively (C). The statistical analysis of methylation frequency is shown (D). E BCL2 protein expression was measured in four AML samples with miR-182 promoter hypomethylation and five AML samples with hypermethylation. *P < 0.05; ***P < 0.001; ****P < 0.0001. ns: Not significant

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us